These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27638045)

  • 21. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
    Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
    Lee SS; Jung SH; Ahn JS; Kim YK; Cho MS; Jung SY; Lee JJ; Kim HJ; Yang DH
    J Korean Med Sci; 2016 Jul; 31(7):1160-3. PubMed ID: 27366017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Grem JL; Kos ME; Evande RE; Meza JL; Schwarz JK
    Cancer; 2015 Nov; 121(21):3862-8. PubMed ID: 26242208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
    Talpur R; Thompson A; Gangar P; Duvic M
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy.
    Koch E; Story SK; Geskin LJ
    Leuk Lymphoma; 2013 Nov; 54(11):2448-51. PubMed ID: 23442065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
    Dunn TJ; Dinner S; Price E; Coutré SE; Gotlib J; Hao Y; Berube C; Medeiros BC; Liedtke M
    Br J Haematol; 2016 Apr; 173(2):253-9. PubMed ID: 27040320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pralatrexate: basic understanding and clinical development.
    Zain J; O'Connor O
    Expert Opin Pharmacother; 2010 Jul; 11(10):1705-14. PubMed ID: 20509772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
    Azaro A; Rodón J; Machiels JP; Rottey S; Damian S; Baird R; Garcia-Corbacho J; Mathijssen RHJ; Clot PF; Wack C; Shen L; de Jonge MJA
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1185-1197. PubMed ID: 27796539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Jennifer C Z; Sara Mohamed J; Salma A; Francine F
    Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
    Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
    Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pralatrexate - from bench to bedside.
    Zain JM; Marchi E
    Drugs Today (Barc); 2010 Feb; 46(2):91-9. PubMed ID: 20393637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors.
    Galsky MD; Camacho LH; Chiorean EG; Mulkerin D; Hong DS; Oh WK; Bajorin DF
    Ann Oncol; 2012 Apr; 23(4):1037-44. PubMed ID: 21828377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.
    Mould DR; Sweeney K; Duffull SB; Neylon E; Hamlin P; Horwitz S; Sirotnak F; Fleisher M; Saunders ME; O'Connor OA
    Clin Pharmacol Ther; 2009 Aug; 86(2):190-6. PubMed ID: 19474785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
    Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
    Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Foss FM; Parker T
    Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pralatrexate, a new hope for aggressive T-cell lymphomas?
    Rueda A; Casanova M; Quero C; Medina-Pérez A
    Clin Transl Oncol; 2009 Apr; 11(4):215-20. PubMed ID: 19380298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pralatrexate (Folotyn).
    Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
    Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use.
    O'Connor OA; Amengual J; Colbourn D; Deng C; Sawas A
    Leuk Lymphoma; 2017 Nov; 58(11):2548-2557. PubMed ID: 28738754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.
    Foss FM; Parker TL; Girardi M; Li A
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e445-e447. PubMed ID: 30181105
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.